Spain
Laminar Pharma, established in 2006, is a pioneering entity within the Biotechnology, Life Sciences, and Pharmaceutical sectors. Based out of Spain, this biopharmaceutical company is making waves with its focus on the groundbreaking "Membrane-Lipid Therapy" (MLT). This innovative approach targets membrane lipids to modulate peripheral protein function, providing a fresh therapeutic strategy against diseases like cancer and neurodegenerative disorders.
Originally emerging as an academic spin-off from the University of the Balearic Islands in Mallorca, Laminar Pharma is led by Prof. Pablo V. Escriba. Their mission is to create next-generation medicines, nutraceuticals, and cosmetics that promise to enhance treatment outcomes for serious conditions such as glioblastoma.
Most recently, the company secured a €5.90M early venture capital investment from the Alba Pérez Foundation on November 1, 2024. This reflects strong investor confidence in Laminar Pharma's potential to redefine medical treatments globally through their pioneering MLT-based drug developments.
